School of Pharmacy Shines Spotlight on Research

Grants Awarded to School Top $9.2 Million

Pharmacy Research SpotlightThe Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy on Jan. 29 announced its researchers received more than $9.2 million in new research funding from January 2018 through January 2019.

More than $8.4 million of the school’s new research funding came from the National Institutes of Health (NIH), including the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute for Neurological Disorders and Stroke (NINDS). Researchers also received funding from the U.S. Department of Defense (DOD), the Society of Toxicology (SOT) and others.  

Quentin Smith, Ph.D., TTUHSC senior vice president for research and School of Pharmacy dean, said the grants focus on research areas related to cancer, cardiovascular health, neuroscience, drug development and women’s health.

“The School of Pharmacy is known for its Pharm.D. program that emphasizes clinical training, but we are equally proud of our science faculty who conduct biomedical and pharmaceutical research focused upon disease mechanisms, drug formulation and delivery, drug synthesis, drug action and clinical practice,” Smith said.

Texas Tech University System Chancellor and TTUHSC President Tedd L. Mitchell, M.D., said the discovery of new knowledge through cutting edge research is a core mission for TTUHSC.

“The School of Pharmacy’s externally funded peer-reviewed research is truly excellent and it is growing rapidly, just as it is throughout TTUHSC,” Mitchell said. “This celebration recognizes the outstanding work of our School of Pharmacy investigators who are committed to making our state and country are healthier through research in various types of drug development. Dean Smith’s leadership will ensure that we continually foster innovation.”


School of Pharmacy researchers who received new grants include:

  • Fakhrul Ahsan, Ph.D., $2,366,265 (NIH), “Recapitulation of Sex Disparity in PAH on a Microfluidic Device and Elucidation of the Differences and Similarities”
  • Ahsan, $108,537 (Cardiovascular Medical Research and Education Fund), “PAH-Mimicking Chip to Elucidate Sex-Based Pathogenesis to Develop Gender-Specific Therapy”
  • Ulrich Bickel, Dr.Med., $28,636 (Therachon), “Pharmacokinetics and Brain Uptake of Recombinant SFGFR3”
  • Hiranmoy Das, Ph.D., $224,999 (NIH), “Development of Nanofiber Expanded CD34+ Stem Cells for Osteoporosis Therapy”  
  • Nadezhda German, Ph.D., and Constantinos Mikelis, Ph.D., $458,847 (NIH/NCI), “Novel Class of Chemotherapeutic Agents for Treatment of Metastatic Triple-Negative Breast Cancer”
  • Rahul Jayant, Ph.D., $153,000 (NIH), “Intranasal Nanodelivery of Oxytocin to Treat Morphine Addiction in HIV Patients by Gene Editing”
  • Jayant, $18,981 (The Campbell Foundation), “Sustained Release of Nano-Medicine Up to One-Month for Treatment of HIV Infection.”
  • Vardan Karamyan, Ph.D., Thomas Abbruscato, Ph.D., and Paul Trippier, Ph.D., $2,915,893 (NIH/NINDS), “Development and Characterization of Peptidomimetic Small Molecule Activators of Peptidase Neurolysin for Stroke Therapy”
  • Ali Keshavarz, $12,500 (International Foundation for Ethical Research), “A Micropattern-Engraved Two-Compartment Tissue-Chip as a Non-Animal Model for Studying Right-Ventricular Hypertrophy Induced by Pulmonary Arterial Hypertension”
  • Devin Lowe, Ph.D., $453,079 (NIH/NCI), “Immunotherapeutic Targeting of Colon Cancer Vascularization to Achieve Long-Term Protective Immunity”
  • Lowe, $542,982 (DOD), “Immunotherapeutic Targeting of Colon Cancer Vascularization to Achieve Long-Term Immunity Against Primary and Metastatic Disease”
  • Eric MacLaughlin, Pharm.D., $7,642 (NIH/NHLBI sub-award), “Dissemination of the Cardiovascular Risk Service (CVRS Live)”
  • Sharavan Ramachadran, M.S., $15,000 (SOT Syngenta Fellowship), “Discovery of Anti-Cancer Effects of Pimavanserin Tartrate in Pancreatic Cancer”
  • Sanjay Srivastava, Ph.D., $23,706 (BePharBel), “Evaluation of Anti-Tumorigenic Effects of Catechin-Lysine Complex in Pancreatic, Breast, Colon, and Lung Cancer in Mice Models”
  • Paul Trippier, Ph.D., $1,876,974 (NIH), “AKR1C3 Inhibitors as Chemotherapeutic Potentiators”

Related Stories

Remembering Dr. Tom McGovern

TTUHSC Celebration of Life Service was held March 25th in remembrance of Tom McGovern, Ed.D.

TTUHSC Ranks Fourth Nationally Among Graduate Institutions as a Military Friendly® School

TTUHSC has been named as a Military Friendly® School for 2022-2023. Among graduate schools, TTUHSC ranked fourth in the nation, achieving Gold award status.

TTUHSC Jerry H. Hodge School of Pharmacy Students Celebrate Residency Assignments on Match Day

On March 16, fourth-year TTUHSC Jerry H. Hodge School of Pharmacy students interested in completing a residency after they graduate in May, learned where they would spend the next stage of their training during the Pharmacy Residency Match Day.

Recent Stories


How Social Media is Impacting Healthcare

Moumita Choudhury Au.D., CCC-A, spoke about the present and future of social media’s impact on healthcare in general and on hearing healthcare specifically.


TTUHSC’s Cornwall Elected Fellow by American Association for the Advancement of Science

Gail Cornwall, Ph.D., professor in the Department of Cell Biology and Biochemistry at the TTUHSC, has been named a member of the American Association for the Advancement of Science Fellowship Class of 2022.


Study Seeks to Improve Pediatric Patient Safety by Addressing Language Barriers

To help address communication hurdles, the Patient-Centered Outcomes Research Institute (PCORI) has awarded a $438,756 subcontract to Tetyana L. Vasylyeva, M.D., Ph.D., from the TTUHSC School of Medicine.